Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.
about
Myotonic Dystrophies: State of the Art of New Therapeutic Developments for the CNS.Biomolecular diagnosis of myotonic dystrophy type 2: a challenging approach.Myopathy With SQSTM1 and TIA1 Variants: Clinical and Pathological Features.Abnormalities in Skeletal Muscle Myogenesis, Growth, and Regeneration in Myotonic Dystrophy.SCN4A as modifier gene in patients with myotonic dystrophy type 2
P2860
Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Myotonic dystrophy type 2 and ...... al and pathomolecular aspects.
@en
Myotonic dystrophy type 2 and ...... al and pathomolecular aspects.
@nl
type
label
Myotonic dystrophy type 2 and ...... al and pathomolecular aspects.
@en
Myotonic dystrophy type 2 and ...... al and pathomolecular aspects.
@nl
prefLabel
Myotonic dystrophy type 2 and ...... al and pathomolecular aspects.
@en
Myotonic dystrophy type 2 and ...... al and pathomolecular aspects.
@nl
P2860
P1476
Myotonic dystrophy type 2 and ...... al and pathomolecular aspects.
@en
P2093
Rosanna Cardani
P2860
P2888
P304
P356
10.1007/S10072-016-2805-5
P577
2017-01-11T00:00:00Z